NCT03338738View on ClinicalTrials.gov

Impact of Beta-lactams on the Microbiota and Relative Fecal Abundance of Mulltidrug Resistant Bacteria

NACompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 19, 2018

Primary Completion Date

March 31, 2021

Study Completion Date

May 28, 2021

Conditions
Enterobacterial Infection
Interventions
DIAGNOSTIC_TEST

Stool culture ans swab

"Patients with ESBL enterobacteria, antibiotic pressure are patients with ESBL positive result diagnosed by stool culture and a rectal swab.~The intervention correspond to addition of 4 stool samples (or 4 rectal swabs in the absence of stool emission) and a blood sample."

Trial Locations (1)

75014

Groupe Hospitalier Paris Saint Joseph, Paris

All Listed Sponsors
collaborator

Hospital Avicenne

OTHER

lead

Fondation Hôpital Saint-Joseph

OTHER

NCT03338738 - Impact of Beta-lactams on the Microbiota and Relative Fecal Abundance of Mulltidrug Resistant Bacteria | Biotech Hunter | Biotech Hunter